全文获取类型
收费全文 | 70篇 |
免费 | 2篇 |
出版年
2021年 | 1篇 |
2020年 | 1篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 11篇 |
2013年 | 5篇 |
2012年 | 1篇 |
2011年 | 2篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 1篇 |
2007年 | 2篇 |
2006年 | 1篇 |
2005年 | 3篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 1篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1985年 | 1篇 |
1980年 | 1篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1955年 | 1篇 |
1954年 | 1篇 |
1951年 | 1篇 |
1946年 | 1篇 |
1945年 | 1篇 |
1942年 | 1篇 |
1940年 | 1篇 |
1938年 | 1篇 |
1936年 | 1篇 |
1931年 | 1篇 |
1929年 | 1篇 |
1923年 | 1篇 |
1920年 | 1篇 |
排序方式: 共有72条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
BACKGROUND: Morbidity management is a core component of the global programme for the elimination of lymphatic filariasis. In a double-blind clinical trial, the tolerability and efficacy of Daflon (500 mg) + DEC (25 mg) or DEC (25 mg) alone, twice daily for 90 days, was studied in 26 patients with bancroftian filarial lymphoedema. RESULTS: None of the patients in either drug group reported any adverse reaction throughout the treatment period (90 days). Haematological and biochemical parameters were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 90) values. The group receiving Daflon showed significant reduction in oedema volume from day 90 (140.6 PlusMinus; 18.8 ml) to day 360 (71.8 PlusMinus; 20.7 ml) compared to the pre-treatment (day 0, 198.4 PlusMinus; 16.5 ml) value. This accounted for a 63.8% reduction in oedema volume by day 360 (considering the pre-treatment (day 0) as 100%). In the DEC group, the changes in oedema volume (between day 1 and day 360) were not significant when compared to the pre-treatment (day 0) value. The percentage reduction at day 360 was only 9%, which was not significant (P > 0.05). CONCLUSION: This study has shown that Daflon (500 mg, twice a day for 90 days) is both safe and efficacious in reducing oedema volume in bancroftian filarial lymphoedema. Further clinical trials are essential for strengthening the evidence base on the role of this drug in the morbidity management of lymphatic filariasis. 相似文献
5.
6.
7.
8.
9.
10.
E. Thomas Everhart Peter Shwonek Peyton Jacob III Michael C. Rowbotham Reese T. Jones 《Journal of chromatography. B, Analytical technologies in the biomedical and life sciences》1999,729(1-2)
A gas chromatographic method for the determination of levorphanol in human plasma is described. The method utilizes extractive alkylation with tetrabutylammonium cation as the phase-transfer catalyst and pentafluorobenzyl bromide as the alkylating agent, and employs a structural analog, d-3-hydroxy-N-ethylmorphinan, as the internal standard. The pentafluorobenzyl ethers formed are separated by capillary gas chromatography and detected by electron capture. The method has good precision and accuracy for concentrations ranging from 0.25 ng/ml to 100 ng/ml and has been used to measure plasma concentrations as part of a study to evaluate the management of chronic neuropathic pain with levorphanol. 相似文献